ACTRIMS 2020: Post-Conference Perspectives
Investigators caution health care providers to consider specific risks of severe COVID-19 infection before initiating this therapy.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Clears Investigational New Drug Application for Remyelinating Agent PTD802 in Multiple Sclerosis
2
Insights on Vibrance-2 Study Results of Alixorexton in Narcolepsy Type 2: Richard K. Bogan, MD, FCCP, FAASM
3
Pipeline Review: Alzheimer Disease Therapies by Mechanism of Action
4
FDA and EMA Accepts Regulatory Applications for Cemdisiran in Generalized Myasthenia Gravis
5